14 November 2024
This announcement contains
inside information as stipulated under the UK version of the Market
Abuse Regulation 596/2014 which is part of English Law by virtue of
the European (Withdrawal) Act 2018, as amended. On publication of
this announcement via a regulatory information service, this
information is considered to be in the public
domain.
BEXIMCO PHARMACEUTICALS
LIMITED.
Financial Results for the
First Quarter Ended 30 September 2024
Beximco Pharmaceuticals Limited
("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP, LEI
No.:213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic
pharmaceutical products and active pharmaceutical ingredients,
today announces its unaudited results for the three-month period
ended 30 September 2024. The financial statements have been
released to the Dhaka and Chittagong Stock Exchanges in compliance
with the requirements from the Bangladesh SEC.
Beximco Pharma Managing Director, Iqbal Ahmed,
commented:
"We have started the year with modest revenue growth in the
face of ongoing macroeconomic challenges. However, as demonstrated
in our recent strong full year results, through the resilience and
underlying strengths of the business, we remain confident in
executing on our growth strategy by providing high-quality and
affordable medicines to patients, and ultimately delivering value
for shareholders."
This announcement is available in
its entirety at http://www.rns-pdf.londonstockexchange.com/rns/1409M_1-2024-11-13.pdf
For
further information please visit www.beximcopharma.com or enquire
to:
Beximco Pharma
S M Rabbur Reza, Chief Operating
Officer
Tel: +880 2 58611001,
Ext.20111
Mohammad Ali Nawaz, Chief Financial
Officer
Tel: +880 2 58611001,
Ext.20030
SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Andrew
Emmott
Tel: +44 (0) 20 3368 3551 /
3555
SP
Angel Corporate Finance LLP (Broker)
Matthew Johnson
Tel: +44 (0) 20 3470 0470
FTI
Consulting
Simon Conway / Victoria Foster
Mitchell / Sam Purewal
Tel: +44 (0) 20 3727 1000
Notes to Editors
About Beximco Pharmaceuticals Limited
Beximco Pharma is a leading
manufacturer and exporter of medicines based in Bangladesh. Since
its inception in 1976, the Company remains committed to health and
wellbeing of people across all the continents by providing access
to contemporary medicines. Company's broad portfolio of generics
encompasses diverse delivery systems such as tablets, capsules,
liquids, semi-solids, intravenous fluids, metered dose inhalers,
dry powder inhalers, sterile ophthalmic drops, insulins, prefilled
syringes, injectables, nebuliser solutions, oral soluble films etc.
The Company also undertakes contract manufacturing for
multinational and leading global generic pharmaceutical
companies.
Beximco Pharma′s state-of-the-art
manufacturing facilities are certified by global regulatory
authorities of USA, Europe, Australia, Canada, GCC and Latin
America, among others and it has a geographic footprint in more
than 50 countries. More than 5700 employees are driving the company
towards achieving its aspiration to be among the most admired
companies in the world.
